Advances in Engineered Macrophages: A New Frontier in Cancer Immunotherapy

Nature·Apr 1

✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source

Researchers are exploring the potential of engineered macrophages in cancer immunotherapy, with various studies and reviews discussing advancements in this field. The use of chimeric antigen receptor (CAR) macrophages and other macrophage-based therapies is being investigated for their potential in treating solid tumors and other types of cancer. These developments may represent a new frontier in cancer immunotherapy, with some outlets also drawing comparisons to CAR T-cell therapy.

Full coverage

Engineering Interferon-γ-Enhanced Chimeric Antigen Receptor Macrophages via Lipid-Assisted Polymeric Nanoparticles for Cancer Immunotherapy

ACS Publications·Jul 4

Macrophage-based therapeutic strategies in glioblastoma: advancements in drug delivery and immunotherapy

Frontiers·Feb 4

CAR-macrophages in solid tumors: promise, progress, and prospects

Nature·Nov 27

CAR-M therapy in the era of tumor immunotherapy: current research progress and engineering strategies

Frontiers·Jan 13

CAR T-Cell Therapy: A New Frontier in Cancer Immunotherapy

Oncodaily·Aug 2

Emerging macrophage-based therapies for cancer: a review of preclinical and clinical advances

Frontiers·Sep 16

From innate-like to innate: the next wave of off-the-shelf CAR immunotherapies

Frontiers·Dec 16

A new era of macrophage-based cell therapy

Nature·Sep 1

View original report at Nature ↗

Fetching the latest headlines…